查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲核酸治療CDMO市場：分析與預測（2023-2033）
市場調查報告書
商品編碼
1428487

歐洲核酸治療CDMO市場：分析與預測（2023-2033）

Europe Nucleic Acid Therapeutics CDMO Market: Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 104 Pages | 商品交期: 1-5個工作天內

價格
主要市場統計數據
預測期 2023-2033
2023年評估價值 12.7億美元
2033年預測 38.8億美元
複合年成長率 11.8%

2023年歐洲核酸治療CDMO市場規模為12.7億美元。預計到 2033 年，市場規模將達到 38.8 億美元，2023-2033 年預測期間複合年成長率為 11.80%。核酸治療 CDMO 市場的推動因素包括慢性病和遺傳性疾病治療中對核酸治療藥物的需求不斷成長、契約製造開發和製造組織 (CDMO) 製造流程的進步、FDA 對核酸治療藥物核准的快速增加以及CDMO 的製造能力。成長由多種因素推動，包括擴張投資的增加。

歐洲核酸治療合約開發和受託製造廠商(CDMO) 市場正在經歷顯著成長。這一市場擴張是由於對核酸療法的需求不斷成長而推動的，以解決該地區流行的慢性病和遺傳疾病。此外，CDMO 製造流程的進步正在提高核酸療法的生產效率和擴充性。此外，FDA 對這些治療方法的核准在該地區不斷增加，顯示接受度和採用率不斷提高。此外，歐洲各地對 CDMO 製造設施擴建的投資不斷增加，進一步推動了市場成長。這種充滿活力的形勢凸顯了該地區對創新和醫療保健進步的承諾，並使歐洲成為全球核酸治療 CDMO 市場的關鍵參與者。

本報告考察了歐洲核酸治療 CDMO 市場，提供了市場概述、化學合成方法的趨勢、國家以及進入市場的公司概況。

目錄

執行摘要

調查範圍

第1章 市場

  • 市場展望
  • 產業展望
  • COVID-19 對核酸療法 CDMO 的影響
  • 核酸治療CDMO形勢
  • 核酸在治療上的重要用途
  • 合成用於治療用途的核酸類型
  • 業務動態

第2章 核酸治療CDMO市場（按地區）

  • 歐洲核酸治療CDMO市場
    • 主要發現
    • 市場動態
    • 市場規模及預測

第3章市場－競爭基準化分析與公司概況

  • 競爭基準化分析
    • 關鍵策略和發展
    • 市場佔有率分析
    • 主要企業視覺圖形
  • 公司簡介
    • AGC Biologics
    • BACHEM
    • Eurofins Scientific
    • LGC Science Group Holdings Limited
    • Merck KGaA
Product Code: BHP1862SS

The Europe Nucleic Acid Therapeutics CDMO Market Expected to Reach $3.88 Billion by 2033

Introduction to Europe Nucleic Acid Therapeutics CDMO Market

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$1.27 Billion
2033 Forecast$3.88 Billion
CAGR11.8%

The Europe nucleic acid therapeutics CDMO market was valued at $1.27 billion in 2023 and is expected to reach $3.88 billion by 2033, growing at a CAGR of 11.80% during the forecast period 2023-2033. The nucleic acid therapeutics CDMO market is experiencing growth due to various factors, these include increasing demand for nucleic acid therapeutics in treating chronic and genetic illnesses, advancements in manufacturing processes by Contract Development and Manufacturing Organizations (CDMOs), a surge in FDA approvals for such therapeutics, and growing investments in expanding CDMO manufacturing capacities.

Market Introduction

The Europe nucleic acid therapeutics Contract Development and Manufacturing Organization (CDMO) market is witnessing significant growth. This expansion is driven by a rising demand for nucleic acid-based treatments to address chronic and genetic diseases prevalent in the region. Additionally, advancements in manufacturing processes by CDMOs are enhancing the production efficiency and scalability of nucleic acid therapeutics. The region has also seen an uptick in FDA approvals for these therapies, indicating growing acceptance and adoption. Moreover, increased investments in expanding CDMO manufacturing facilities across Europe are further fueling market growth. This dynamic landscape underscores the region's commitment to innovation and healthcare advancement, positioning Europe as a key player in the global nucleic acid therapeutics CDMO market.

Market Segmentation:

Segmentation 1: by Chemical Synthesis Method

  • Solid-Phase Oligonucleotide Synthesis
  • Liquid-Phase Oligonucleotide Synthesis

Segmentation 2: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The Europe nucleic acid therapeutics CDMO market has been extensively segmented based on various categories, such as chemical synthesis method and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: Key players in the Europe nucleic acid therapeutics CDMO market analysed and profiled in the study involve established players that offer various kinds of nucleic acid therapeutics CDMO products.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some prominent names established in this market are:

  • AGC Biologics
  • BACHEM
  • Eurofins Scientific
  • LGC Science Group Holdings Limited
  • Merck KGaA

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Market

  • 1.1 Market Outlook
    • 1.1.1 Market Overview
    • 1.1.2 Product Definition
    • 1.1.3 Inclusion and Exclusion Criteria
    • 1.1.4 Key Findings
  • 1.2 Industry Outlook
    • 1.2.1 Key Trends
      • 1.2.1.1 Significant Number of Collaborations among Market Players
      • 1.2.1.2 Increasing Investment for Expansion of Nucleic Acid Therapeutics CDMO Manufacturing Units
      • 1.2.1.3 CDMOs Shifting their Business Strategy in Response to a Changing Environment
    • 1.2.2 Opportunity Assessment
    • 1.2.3 Patent Analysis
      • 1.2.3.1 Awaited Technological Developments
      • 1.2.3.2 Patent Filing Trend (by Country)
      • 1.2.3.3 Patent Filing Trend (by Year)
    • 1.2.4 Production Capability
    • 1.2.5 Preferred Techniques By CDMO
      • 1.2.5.1 Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
      • 1.2.5.2 Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
      • 1.2.5.3 Preferred Techniques by CDMOs for Nucleic Acid Purification
    • 1.2.6 Factors Considered While Outsourcing To CDMO.
    • 1.2.7 Regulatory Framework
  • 1.3 Impact of COVID-19 on the Nucleic Acid Therapeutics CDMO
    • 1.3.1 Pre-COVID-19 Phase
    • 1.3.2 During COVID-19
    • 1.3.3 Post-COVID-19 Phase
      • 1.3.3.1 Impact on Demand and Supply
  • 1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
  • 1.5 Significant Usage of Nucleic Acid in Therapeutics
  • 1.6 Types of Nucleic Acid Synthesized for Therapeutics
    • 1.6.1 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
    • 1.6.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)
    • 1.6.3 MicroRNAs (miRNAs)
    • 1.6.4 RNA Aptamers and RNA Decoys
    • 1.6.5 Ribozymes
    • 1.6.6 Circular RNAs
  • 1.7 Business Dynamics
    • 1.7.1 Impact Analysis
    • 1.7.2 Business Drivers
      • 1.7.2.1 Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
      • 1.7.2.2 Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
      • 1.7.2.3 Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs
    • 1.7.3 Business Restraints
      • 1.7.3.1 Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
      • 1.7.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutic
    • 1.7.4 Business Opportunities
      • 1.7.4.1 Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses.
      • 1.7.4.2 Pharmaceutical Firms Becoming More Outsourcing-Oriented

2 Nucleic Acid Therapeutics CDMO Market (by Region)

  • 2.1 Europe Nucleic Acid Therapeutics CDMO Market
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
      • 2.1.2.1 Impact Analysis
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2 Europe Nucleic Acid Therapeutics CDMO Market (by Country)
        • 2.1.3.2.1 Germany
          • 2.1.3.2.1.1 Germany Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 2.1.3.2.2 U.K.
          • 2.1.3.2.2.1 U.K. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 2.1.3.2.3 France
          • 2.1.3.2.3.1 France Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 2.1.3.2.4 Spain
          • 2.1.3.2.4.1 Spain Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 2.1.3.2.5 Italy
          • 2.1.3.2.5.1 Italy Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 2.1.3.2.6 Rest-of-Europe
          • 2.1.3.2.6.1 Rest-of-Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Competitive Benchmarking
    • 3.1.1 Key Strategies and Developments
      • 3.1.1.1 Funding Activities
      • 3.1.1.2 New Offerings
      • 3.1.1.3 Mergers and Acquisitions
      • 3.1.1.4 Partnerships and Collaborations
      • 3.1.1.5 Business Expansions
      • 3.1.1.6 Regulatory and Legal Activities
    • 3.1.2 Market Share Analysis
    • 3.1.3 Visual Graphics of Key Companies
  • 3.2 Company Profile
    • 3.2.1 AGC Biologics
      • 3.2.1.1 Company Overview
      • 3.2.1.2 Role of AGC Biologics in the Nucleic Acid Therapeutics CDMO Market
      • 3.2.1.3 Financials
      • 3.2.1.4 Recent Developments
      • 3.2.1.5 Analyst Perspective
    • 3.2.2 BACHEM
      • 3.2.2.1 Company Overview
      • 3.2.2.2 Role of BACHEM in the Nucleic Acid Therapeutics CDMO Market
      • 3.2.2.3 Financials
      • 3.2.2.4 Recent Developments
      • 3.2.2.5 Analyst Perspective
    • 3.2.3 Eurofins Scientific
      • 3.2.3.1 Company Overview
      • 3.2.3.2 Role of Eurofins Scientific in the Nucleic Acid Therapeutics CDMO Market
      • 3.2.3.3 Financials
      • 3.2.3.4 Recent Developments
      • 3.2.3.5 Analyst Perspective
    • 3.2.4 LGC Science Group Holdings Limited
      • 3.2.4.1 Company Overview
      • 3.2.4.2 Role of LGC Science Group Holdings Limited in the Nucleic Acid Therapeutics CDMO Market
      • 3.2.4.3 Recent Developments
      • 3.2.4.4 Analyst Perspective
    • 3.2.5 Merck KGaA
      • 3.2.5.1 Company Overview
      • 3.2.5.2 Role of Merck KGaA in the Nucleic Acid Therapeutics CDMO Market
      • 3.2.5.3 Financials
      • 3.2.5.4 Recent Developments
      • 3.2.5.5 Analyst Perspective

List of Figures

  • Figure 1: Services Offered by CDMOs
  • Figure 2: Europe Nucleic Acid Therapeutics CDMO Market, Impact Analysis
  • Figure 3: Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), % Share, 2022 and 2033
  • Figure 4: Nucleic Acid Therapeutics CDMO Market (by Region), $Billion, 2022 and 2033
  • Figure 5: Europe Nucleic Acid Therapeutics CDMO Market: Research Methodology
  • Figure 6: Primary Research Methodology
  • Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 8: Top-Down Approach (Segment-Wise Analysis)
  • Figure 9: Significant Number of Collaborations among Market Players in Nucleic Acid Therapeutics CDMO Market, 2019-2023
  • Figure 10: Core CDMO Services
  • Figure 11: Nucleic Acid Therapeutics CDMO Market Key Trends, Market Shift, 2022-2033
  • Figure 12: Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Country), January 2018-January 2023
  • Figure 13: Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Year), January 2018-December2022
  • Figure 14: Synthesis Capabilities of Key Companies
  • Figure 15: Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
  • Figure 16: Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
  • Figure 17: Preferred Techniques by CDMOs for Nucleic Acid Purification
  • Figure 18: Factors considered while outsourcing to CDMO.
  • Figure 19: Nucleic Acid Therapeutics CDMO Market, Impact Analysis
  • Figure 20: Significant Increase in Sale of TEGSEDI and WAYLIVRA Drugs in $Million, 2018-2021
  • Figure 21: Significant Number of Nucleic Acid Drugs Approved by FDA or EMA in Nucleic Acid Therapeutics CDMO Market, 2018-2020
  • Figure 22: Nucleic Acid Therapeutics CDMO Market Share (by Region), 2022-2033
  • Figure 23: Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 24: Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 25: Europe Nucleic Acid Therapeutics CDMO Market (by Country), Share (%), 2022 and 2033
  • Figure 26: Germany Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 27: Germany Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 28: U.K. Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 29: U.K. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 30: France Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 31: France Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 32: Spain Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 33: Spain Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 34: Italy Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 35: Italy Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 36: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 37: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 38: Nucleic Acid Therapeutics CDMO Market, Number of Key Developments and Strategies, January 2018-February 2023
  • Figure 39: Funding Activities, January 2018-February 2023
  • Figure 40: New Offerings, January 2018-February 2023
  • Figure 41: Mergers and Acquisitions, January 2018-February 2023
  • Figure 42: Partnerships and Collaborations, January 2018-February 2023
  • Figure 43: Business Expansions, January 2018-February 2023
  • Figure 44: Regulatory and Legal Activities, January 2018-February 2023
  • Figure 45: Nucleic Acid Therapeutics CDMO Market, Company Revenue Share Analysis, $Billion, 2022
  • Figure 46: Some of the Active Players in the Nucleic Acid Therapeutics CDMO Market
  • Figure 47: AGC Biologics: Product Portfolio
  • Figure 48: AGC Biologics: Overall Financials, $Million, 2019-2021
  • Figure 49: AGC Biologics: Segment Revenues, $Million, 2019-2021
  • Figure 50: AGC Biologics: Net Revenue (by Region), $Million, 2020-2021
  • Figure 51: BACHEM: Product Portfolio
  • Figure 52: BACHEM: Overall Financials, $Million, 2020-2022
  • Figure 53: BACHEM: Net Revenues (by Segment), $Million, 2020-2022
  • Figure 54: BACHEM: Net Revenue (by Region), $Million, 2020-2022
  • Figure 55: BACHEM: R&D Expenditure, $Million, 2020-2022
  • Figure 56: Eurofins Scientific: Product Portfolio
  • Figure 57: Eurofins Scientific: Overall Financials, $Million, 2020-2022
  • Figure 58: Eurofins Scientific: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 59: Eurofins Scientific: Net Revenue (by Region), $Million, 2020-2022
  • Figure 60: LGC Science Group Holdings Limited: Product Portfolio
  • Figure 61: LGC Science Group Holdings Limited: Overall Financials, $Million, 2020-2022
  • Figure 62: LGC Science Group Holdings Limited: Net Revenue (by Segment), $Million, 2021-2022
  • Figure 63: LGC Science Group Holdings Limited: Net Revenue (by Region), $Million, 2020-2022
  • Figure 64: LGC Science Group Holdings Limited: R&D Expenditure, $Million, 2020-2022
  • Figure 65: Merck KGaA: Product Portfolio
  • Figure 66: Merck KGaA: Overall Financials, $Million, 2020-2022
  • Figure 67: Merck KGaA: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 68: Merck KGaA: Net Revenue (by Region), $Million, 2020-2022
  • Figure 69: Merck KGaA: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Nucleic Acid Therapeutics CDMO Market, Key Developments Analysis, January 2018-February 2023
  • Table 2: Key Questions Answered in the Report
  • Table 3: Some of the Partnerships and Collaborations in the Nucleic Acid Therapeutics CDMO Market
  • Table 4: Nucleic Acid Therapeutics CDMO Market, Key Investment
  • Table 5: Regulatory Organization: Nucleic Acid Therapeutics CDMO Market
  • Table 6: Nucleic Acid Drugs Approved by FDA or EMA, 2018-2021
  • Table 7: Advancements in Manufacturing Units of CDMO
  • Table 8: Europe Nucleic Acid Therapeutic CDMO Market, Impact Analysis